Skip to main content
. 2026 Jul 21;18(14):2349. doi: 10.3390/cancers18142349
ACTH Adrenocorticotropic hormone
BORR Best observed response
CR Complete remission
FT4 Free-T4 (tetraiodothyronine)
DOB Date of birth
HIPAA Health Insurance Portability and Accountability Act
ICI Immune checkpoint inhibitors
I+N Ipilimumab plus nivolumab
irAE Immune-related adverse events
IRB Institutional review board
LAG-3 Lymphocyte-activation gene 3
LDH Lactate dehydrogenase
N+R Nivolumab plus relatlimab
OS Overall survival
PFS Progression-free survival
PD Progressive disease
PR Partial response
SD Stable disease
Tg Thyroglobulin
TPO Thyroid peroxidase
TSH Thyroid stimulating hormone
TSHR Thyroid stimulating hormone receptor